abstract: PURPOSE: The purpose of this pilot study was to evaluate the safety and efficacy of @entity4580 ophthalmic solution 1% in @entity1 with @entity936 ( @entity936 ). METHODS: This was a 4-week, single-center, open-label clinical trial in @entity1 diagnosed with @entity936 using the Contact Lens Dry Eye Questionnaire (CLDEQ). Fifty @entity1 were enrolled in this study. The @entity1 were randomized to 1 of 2 treatment groups: @entity4580 ophthalmic solution administered bid on days 1 and 2 and on days 3 to 29  1 or Visine for Contacts rewetting drops administered qid on days 1 to 29  1. The @entity1 diaries were used daily to collect data on comfortable and total contact lens wear time and ocular dryness throughout the treatment period. Tear osmolarity, @entity941 corneal staining, and visual acuity were also assessed during clinic visits. RESULTS: Fifty @entity1 were enrolled, and 44 completed the study. One @entity1 discontinued in the @entity4580 group, and five @entity1 discontinued in the rewetting drops group because of adverse events. A statistically significant increase in mean comfortable contact lens wear time from baseline was observed for the subjects treated with @entity4580 ophthalmic solution as compared with the subjects treated with rewetting drops at week 4 (P=0.004; primary endpoint), in addition to weeks 2 and 3. The improvement in the mean comfortable wear time for the @entity1 in the @entity4580 treatment group exceeded 2 hrs throughout the treatment period (weeks 1-4). No significant differences were observed between the groups for total wear time, low contrast visual acuity, or tear osmolarity. Subject-rated ocular dryness (PM time assessments) was significantly improved from baseline in the subjects treated with @entity4580 ophthalmic solution as compared with those treated with rewetting drops at weeks 2 and 3 endpoints (P=0.015 for each week). Additionally, a statistical difference was observed in favor of the @entity4580 treatment group at week 2 for the subjects reclassifying as nondry eye as determined by the CLDEQ (P=0.05). CONCLUSIONS: Treatment with topical @entity4580 ophthalmic solution was well tolerated and resulted in a significant improvement in comfortable contact lens wear time in the @entity1 with @entity936 .

title: Safety and efficacy of topical @entity4580 ophthalmic solution 1.0% in the treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity936 :: ('MESH:D015352', 'Disease') :: ['CLDE', 'contact lens-related dry eye']

entities_list: @entity4580 :: ('MESH:D017963', 'Chemical') :: ['azithromycin']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']

answer: @entity936 :: (MESH:D015352,Disease) :: ['contact lens-related dry eye']


abstract: UNASSIGNED: @entity3841 (Aa) is a pathobiont and part of a consortium of bacteria that can lead to @entity2521 in @entity1 . Our aim was to develop a model for oral inoculation of labeled Aa into a suitable host in order to study Aa traits and ecological factors that either enhance or repress its persistence. Primate species were screened for Aa to select a host for colonization studies. @entity2608 (Rhesus/Rh) was selected. Rh Aa strains were isolated, subjected to sequencing and functional analysis for comparison to @entity1 strains. "Best" methods for microbial decontamination prior to inoculation were assessed. Three groups were studied; Group 1 (N=5) was inoculated with Aa Spectinomycin resistant (SpecR) Rh strain 4.35, Group 2 (N=5) inoculated with Aa SpecR @entity1 @entity818 781, and Group 3 (N=5) the un-inoculated control. Repeated feeding with pancakes spiked with SpecRAa followed high dose oral inoculation. Cheek, tongue, and plaque samples collected at baseline 1, 2, 3, and 4 weeks after inoculation were plated on agar; 1) selective for Aa, 2) enriched for total counts, and 3) containing 50   g/ml of Spec. Aa was identified by colonial morphology and DNA analysis. Rh and @entity1 Aa had > 93-98 % genome identity. Rh Aa attached to tissues better than @entity818 781 in vitro (p < 0.05). SpecR @entity818 781 was not recovered from any tissue at any time; whereas, RhSpecR 4.35 was detected in plaque, but never tongue or cheek, in all monkeys at all times (> 1 * 10(5) colonies/ml; p < 0.001). In conclusion, the primate model provides a useful platform for studying integration of Aa strains into a reduced but established oral habitat. Primate derived SpecRAa was consistently detected in plaque at all collection periods; however, @entity1 derived Aa was never detected. The model demonstrated both microbial as well as tissue specificity.

title: Colonization and Persistence of Labeled and "Foreign" Strains of @entity3841 Inoculated into the Mouths of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human strain', 'humans', 'human']

entities_list: @entity2521 :: ('MESH:D010518', 'Disease') :: ['periodontitis']

entities_list: @entity3841 :: ('714', 'Species') :: ['Aggregatibacter actinomycetemcomitans']

entities_list: @entity2608 :: ('9544', 'Species') :: ['Macaca mulatta']

answer: @entity2608 :: (9544,Species) :: ['Rhesus Monkeys']


abstract: UNASSIGNED: e14078 Background: The Adjuvant @entity694 with @entity901 ( @entity901 )/5-FU (ACCElox) Registry was established in 2006 to record treatment and outcome information for @entity1 with @entity694 in the Asia-Pacific, Latin America, the Middle East and Africa. METHODS: Data were collected on @entity1 /disease characteristics, treatments, adverse events and outcomes at registry entry, before each treatment, at treatment discontinuation and 6, 12, 24 and 36 months post treatment. The primary objective was to assess how adjuvant @entity901 /5-FU-based regimens are used in clinical practice, versus approved regimens and the clinical-trial experience. RESULTS: By May 2010, 1,548 evaluable @entity1 had been recruited (1,315 [84.9%] of which were treated with FOLFOX [5-FU + @entity4181 + @entity901 ]: median age 58.2 years, range 18.2-89.2; 56.7% @entity1 ; 72.7% stage III, 27.3% stage II @entity694 ). The median number of cycles of FOLFOX received (based on @entity901 administration) was 12, which is in line with the recommended number. The median dose received of each component of the regimen over the treatment course closely reflected the recommended dose (Table). 69% (n=884) of @entity1 receiving >= 2 cycles had a treatment delay of >= 4 days; among these, dose delays were mainly due to adverse events (43%, of which platelet, @entity548 and clotting disorders=25% and white cell and @entity74 =65%) or personal convenience reasons (37%). The majority of @entity1 completed the treatment course (n=985, 75%). Among those who discontinued treatment (n=328), physician/ @entity1 refusal (n=124, 38%) and adverse events (n=103, 31%) were the primary reasons. CONCLUSIONS: FOLFOX is the most common @entity901 /5-FU-based regimen used and appears to be applied in clinical practice in line with the approved regimen. Outcome data from this cohort will be reported at a later date. [Table: see text].

title: Global clinical experience with adjuvant @entity901 /5-fluorouracil (5-FU)-based chemotherapy for XXXX : ACCElox registry.

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin', 'Eloxatin']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men']

entities_list: @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['reticuloendothelial disorders']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['Colon Cancer', 'colon cancer']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colon cancer']


abstract: UNASSIGNED: 4052 Background: @entity418 commonly expresses cyclo-oxygenase II ( @entity2247 ). @entity2247 inhibition results in decreased cell proliferation and potentiation of chemotherapy and @entity1161 . We reported the preliminary results of a phase II study conducted by the HOG in @entity1 (pts) with potentially resectable @entity418 (ASCO 2003, A 1168). METHODS: All pts received @entity900 (75 mg/m2 d1, 29) and @entity1487 (1000 mg/m2 d1-4, 29-32) with @entity1161 (50.4Gy beginning d1). @entity12698 was administered 200 mg po bid from d1 daily until surgery and then 400 mg po bid until disease progression or excessive @entity137 or a maximum of 5 years. Esophagectomy was performed 4 -6 weeks after the completion of chemoradiation. The primary endpoint was pathological complete response (pCR). Secondary endpoints included response rate, @entity137 , overall survival and correlation between @entity2247 expression and pCR. RESULTS: Thirty-one pts were enrolled from 3/01 to 7/02. Of the 22 pts (71%) who underwent surgery 6 had pCR (19% of those enrolled and 27% of those who underwent surgery). The two year survival rate (Kaplan-Meier estimate) for the entire study population was 31%  12% with a median survival of 17 months. @entity2247 expression was performed and graded weak (0 or 1+) or strong (2+ or 3+) on 17 available baseline @entity418 tissue specimens. Out of 17 evaluable pre therapy specimens, 10 (59%) had strong @entity2247 expression. The two-year survival rates for those with weak and strong baseline @entity2247 expression were similar (0.38  0.20 Vs. 0.40    0.15, p=0.473). However, the two year survival was significantly improved in @entity1 who achieved pCR compared to those who did not (0.50  0.35 Vs. 0.26  0.11, p=0.027). CONCLUSIONS: 1) Baseline @entity2247 expression in @entity418 tissues does not predict survival in @entity1 with @entity418 treated with @entity900 , @entity1487 , @entity12698 and @entity1161 treatment followed by surgery. 2) Pathological complete response following induction chemoradiation is associated with improved survival. [Table: see text].

title: A phase II study of @entity900 , XXXX ( @entity1487 ), @entity1161 ( @entity1161 ) and @entity12698 in @entity1 with resectable @entity418 ( @entity418 ): Updated results from the Hoosier Oncology Group (HOG) study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib', 'Celecoxib']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer', 'EC']

answer: @entity1487 :: (MESH:D005472,Chemical) :: ['5 fluorouracil']


abstract: The present study aimed to clarify the efficacy of extensive surgery, including pancreas head resection, for more complete lymphadenectomy in the treatment of @entity1086 . The study involved retrospective analyses of 65 consecutive @entity1 with @entity1086 who underwent surgical resection between 1982 and 2003. Of these 65 @entity1 , 41.5% displayed @entity1817 and among them 23.1% had positive para-aortic nodes. Of six node-positive 5-year survivors, five underwent pancreatoduodenectomy combined with S4aS5 hepatic subsegmentectomy. The 5-year survival rates were 76.2% for pN0, 30.0% for @entity3121 , 45.8% for @entity477 , and 0% for pM1[lymph], respectively. Significant differences existed in survival rates. Postoperative recurrence was observed in 24.1% (13/54) of @entity1 who underwent R0 resection. Of the four @entity1 who displayed lymph node recurrence, two had pericholedocal and/or posterior pancreatoduodenal lymph node @entity3 at the time of surgery and underwent pancreas-preserving regional lymphadenectomy. These results suggest that extensive resection, including resection of the pancreatic head, is effective in selected @entity1 with up to @entity477 lymph node @entity3 , as @entity5 can be achieved. Pancreatoduodenectomy combined with S4aS5 hepatic subsegmentectomy should be considered when lymph node @entity3 is obvious and the @entity1 is in good condition.

title: Significance of extensive surgery including resection of the pancreas head for the treatment of XXXX --from the perspective of mode of lymph node involvement and surgical outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['long as complete removal of the cancer']

entities_list: @entity1817 :: ('MESH:D012804', 'Disease') :: ['node-positive disease']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1086 :: ('MESH:D005706', 'Disease') :: ['gallbladder carcinoma']

answer: @entity1086 :: (MESH:D005706,Disease) :: ['gallbladder cancer']


abstract: STUDY DESIGN: A case report of a @entity1 with @entity1688 as a result of @entity1264 who had cervical laminectomy for spinal cord decompression followed by occipitocervical instrumentation is described. OBJECTIVES: To describe the consequences of severe @entity1264 and an effective surgical technique of occipitocervical instrumentation. SUMMARY OF BACKGROUND DATA: @entity1264 is one of the most commonly @entity74 in the @entity1 population. Extensive intraspinal involvement by @entity3292 can cause significant distortion of normal spinal structure as well @entity1745 . Extensive laminectomy (with subsequent risk of postsurgical @entity1513 ) is often required for adequate decompression of the spinal cord. METHODS: The clinical and radiographic presentation of a @entity1 with severe @entity1264 resulting in @entity1688 is described. The severe @entity51 was caused by compression of the spinal cord by intraspinal @entity3292 . Extensive laminectomy was required to adequately decompress the spinal cord. Occipitocervical fusion from the occiput to C6 was done to stabilize the spine and prevent future @entity1513 . RESULTS: Decompression of the spinal cord led to complete neurologic recovery, and instrumentation of the cervical spine was successful in preventing the development of @entity1513 in this pediatric @entity1 . CONCLUSIONS: The reported case emphasizes the need for treating @entity16 caused by @entity1745 in @entity1264 as well as addressing the future risk of @entity85 following laminectomy.

title: @entity1688 in a 10 year-old XXXX due to multiple cervical @entity3292 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patient', 'child']

entities_list: @entity1688 :: ('MESH:D011782', 'Disease') :: ['quadriplegia']

entities_list: @entity1513 :: ('MESH:D007738', 'Disease') :: ['postlaminectomy kyphosis', 'kyphosis']

entities_list: @entity3292 :: ('MESH:D009455', 'Disease') :: ['neurofibromas']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['acute neurologic symptoms']

entities_list: @entity1264 :: ('MESH:D009456', 'Disease') :: ['Neurofibromatosis type I', 'neurofibromatosis type I']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurologic deficit']

entities_list: @entity1745 :: ('MESH:D013117', 'Disease') :: ['spinal cord compression']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['inherited genetic disorders']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['spinal deformity']

answer: @entity1 :: (9606,Species) :: ['boy']


abstract: BACKGROUND AND OBJECTIVES: Studies have shown decreased bone mineral density in individuals with @entity1791 , but their burden of @entity174 remains unclear. This study sought to determine whether @entity1791 is associated with increased @entity174 risk across the lifespan and to delineate sex effects. DESIGN, SETTING, @entity1 , _ MEASUREMENTS: A population-based retrospective cohort study using The Health Improvement Network was performed. The median calendar year for the start of the observation period was 2004 (1994-2012). This study identified 51,785 @entity1 with >= 1 of 87 diagnostic codes for @entity1791 and 517,267 randomly selected age-, sex-, and practice-matched @entity1 . Cox regression was used to estimate the hazard ratio (HR) for first @entity174 . Fractures identified using diagnostic codes were classified by anatomic site. RESULTS: Median age was 53 years, and 67% of @entity1 were @entity1 , confirming their greater @entity1791 burden. Median time from @entity1791 diagnosis to @entity174 was 10 years. The HR for @entity174 associated with @entity1791 differed by sex and age (P for interactions, P <=0.003). In @entity1 , the adjusted HR was greatest in adolescence (1.55; 95% confidence interval [95% CI], 1.07 to 2.25) with an overall HR of 1.10 (95% CI, 1.05 to 1.16). @entity1791 was associated with higher @entity174 risk in @entity1 aged 30-79 years (HR, 1.17-1.52), and was highest in @entity1 aged 30-39 years (HR, 1.52; 95% CI, 1.23 to 1.87). Peak background @entity174 rates were highest in @entity1 aged 10-19 years and in @entity1 aged 70-79 years. The incidence per 10,000 @entity1 -years in @entity1 with versus without @entity1791 was 392 versus 258 in male @entity1 aged 10-19 years, and 263 versus 218 in @entity1 aged 70-79 years. Distribution of @entity174 site within sex did not differ between @entity1 with versus without @entity1791 . CONCLUSIONS: @entity1791 was associated with higher incident @entity174 risk. The significantly higher risk at times of peak background @entity174 incidence in adolescent @entity1 and elderly @entity1 has profound public health implications.

title: Risk of @entity174 in XXXX : A Population-Based Cohort Study Using the Health Improvement Network.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'person', 'PARTICIPANTS', 'boys', 'men']

entities_list: @entity1791 :: ('MESH:D052878', 'Disease') :: ['urolithiasis', 'Urolithiasis']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

answer: @entity1791 :: (MESH:D052878,Disease) :: ['Urolithiasis']


abstract: Initiation of the development of the anterior-posterior axis in the @entity19 embryo has been thought to take place only when the anterior visceral endoderm (AVE) emerges and starts its asymmetric migration. However, expression of @entity29922 , a marker of the AVE, was recently found to initiate before embryo implantation. This finding has raised two important questions: are the cells that show such early, preimplantation expression of this AVE marker the real precursors of the AVE and, if so, how does this contribute to the establishment of the AVE? Here, we address both of these questions. First, we show that the expression of another AVE marker, @entity64340 , also commences before implantation and its expression becomes consolidated in the subset of ICM cells that comprise the primitive endoderm. Second, to determine whether the cells showing this early @entity64340 expression are true precursors of the AVE, we set up conditions to trace these cells in time-lapse studies from early periimplantation stages until the AVE emerges and becomes asymmetrically displaced. We found that @entity64340 -expressing cells are asymmetrically located after implantation and, as the embryo grows, they become dispersed into two or three clusters. The expression of @entity64340 in the proximal domain is progressively diminished, whilst it is reinforced in the distal-lateral domain. Our time-lapse studies demonstrate that this distal-lateral domain is incorporated into the AVE together with cells in which @entity64340 expression begins only after implantation. Thus, the AVE is formed from both part of an ancestral population of Cerl-expressing cells and cells that acquire @entity64340 expression later. Finally, we demonstrate that when the AVE shifts asymmetrically to establish the anterior pole, this occurs towards the region where the earlier postimplantation expression of @entity64340 was strongest. Together, these results suggest that the orientation of the anterior-posterior axis is already anticipated before AVE migration.

title: The anterior visceral endoderm of the XXXX embryo is established from both preimplantation precursor cells and by de novo gene expression after implantation.

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: OBJECTIVE: Appropriate treatment for scorpion-associated @entity158 was not previously studied in detail in the literature. The aim of this study was to compare the efficacy of three treatment modalities in @entity1 with @entity158 using visual analog scale (VAS) scores. MATERIALS AND METHODS: A randomized study was carried out during a 1-year period in @entity1 with scorpion stings who did not have any systemic signs or symptoms. @entity1 were treated with intravenous @entity1443 , topical @entity3303 , or ice application. @entity158 intensity was evaluated using VAS score at the time of presentation to emergency department and at 30th, 60th, 120th, and 240th minutes. Changes in VAS scores from baseline were recorded. RESULTS: A total of 130 @entity1 were included in the statistical analysis. Significant reduction in @entity158 intensity was observed with topical @entity3303 group when compared with the ice application group (p < 0.001) and @entity1443 group (p < 0.001) in all selected time intervals. The median reduction in scores at 30 min after therapeutic intervention was 25.0 mm for topical @entity3303 , 14.5 mm for ice application, and 10.0 mm for intravenous @entity1443 . No adverse events were reported. DISCUSSION: Our results revealed that topical @entity3303 is superior to both intravenous @entity1443 and local ice application and its effect lasts several hours after @entity5900 . CONCLUSION: Topical @entity3303 is an effective and safe treatment in scorpion sting associated with @entity158 in @entity1 with nonsystemic signs and symptoms.

title: A randomized trial comparing intravenous @entity1443 , topical XXXX , and ice application for treatment of @entity158 associated with scorpion stings.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain', 'painful scorpion stings']

entities_list: @entity1443 :: ('MESH:D000082', 'Chemical') :: ['paracetamol']

entities_list: @entity5900 :: ('MESH:D012909', 'Disease') :: ['envenomation']

answer: @entity3303 :: (MESH:D008012,Chemical) :: ['lidocaine']


abstract: INTRODUCTION AND OBJECTIVES: Non-transitional cell @entity5 of the bladder are both a diagnostic challenge for the pathologist and a therapeutic challenge for the urologist, because although uncommon (less than 5% of all @entity5 of the bladder) they show different biological behaviours each requiring a unique approach. The most significant pathoanatomical types are: primary @entity957 , primary @entity420 and @entity242 . This paper presents an analysis of our experience in these types of @entity5 . MATERIAL AND METHODS: A retrospective study of unusual cases of @entity150 seen in our hospital between 1988-2001. Their biological behaviour and the therapies applied are analysed. The extravesical origin of the @entity5 was ruled out in all cases. RESULTS: We found 21 cases of the following pathoanatomical varieties: 13 @entity957 , 7 @entity420 (3 urachal) and 1 @entity242 . Mean age was very different between @entity957 (69.2 +/- 9.1 years) and @entity420 (50.3 +/- 8.1). Tumour behaviour was very aggressive in all three histological varieties. At the time of diagnosis 19 @entity1 had locally advanced stages (> or = T2). Although elective therapy was cystectomy, this was only feasible in 10 cases. Systemic chemotherapy (most frequently M-VAC) and/or local radiotherapy was used in 7 cases. 14 @entity1 have died after a mean survival of 15.7 +/- 11.6 months. CONCLUSIONS: Late diagnosis of these @entity5 and their aggressive biological behaviour involve a gloomy prognosis. Only early diagnosis and radical therapy could improve the prognosis.

title: [Unusual @entity150 : primary XXXX , @entity420 , and @entity242 . Clinical behavior. Our experience].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'primary sarcoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'malignancies', 'tumour']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['epidermoid carcinomas', 'epidermoid carcinoma']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['cancer of the bladder']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma']

answer: @entity957 :: (MESH:D002294,Disease) :: ['epidermoid carcinoma']


abstract: OBJECTIVE: After thromboembolectomy, @entity1 with @entity63 often receive anticoagulant therapy to prevent recurrent events. @entity1 with @entity955 or cardiac @entity715 have a higher risk of recurrent emboli than those without these risk factors. This study examines the importance of long-term anticoagulation in these 2 groups. DESIGN: A review of @entity1 presenting with @entity63 over a 5-year period (1994-1999). SETTING: A university-affiliated medical centre. @entity1 : Fifty @entity1 divided into 2 groups: 19 (38%) @entity1 with @entity955 (group 1) and 31 (62%) @entity1 with no @entity955 or cardiac @entity715 (group 2) as confirmed by transthoracic echocardiography. INTERVENTION: All @entity1 underwent surgical thromboembolectomy and received postoperative anticoagulant therapy. OUTCOME MEASURES: Mortality, limb loss, further @entity1031 and @entity548 complications as determined by telephone survey. RESULTS: There was a significant difference in 5-year survival (group 1, 84%; group 2, 64%) and early limb loss (group 1, 0%; group 2, 13%). Further @entity1031 and @entity548 complications were rare but were more common in group 1. In group 2 there were no instances of recurrent thromboemboli and no @entity548 complications although only 39% of @entity1 in this group were taking angicoagulants at the end of the study period. CONCLUSIONS: @entity1 with extremity thromboemboli without @entity955 or cardiac @entity715 may not be at the same risk for recurrent events as those with these risk factors, and long-term anticoagulant therapy may not be as necessary in this group.

title: Is long-term anticoagulation after acute XXXX always necessary?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['acute limb ischemia']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic events']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

answer: @entity1031 :: (MESH:D013923,Disease) :: ['thromboembolic limb ischemia']


abstract: UNASSIGNED: The aim of this study was to investigate the effect of errors during practice on motor skill learning in young individuals with @entity306 ( @entity306 ). Minimizing errors has been validated in typically developing @entity1 and @entity1 with @entity717 as a method for implicit learning, because it reduces working memory involvement during learning. The present study assessed whether a practice protocol that aims at minimizing errors can induce implicit learning in young individuals with @entity306 as well. Accordingly, we hypothesized that reducing errors during practice would lead to enhanced learning and a decrease in the dependency of performance on working memory. Young individuals with @entity306 practiced an aiming task following either an error-minimizing (N=20) or an error-strewn (N=18) practice protocol. Aiming accuracy was assessed in pre-, post- and retention test. Dual task performance was assessed to establish dependency on working memory. The two practice protocols did not invoke different amounts or types of learning in the @entity1 with @entity306 . Yet, @entity1 improved aiming accuracy and showed stable motor performance after learning, irrespective of the protocol they followed. Across groups the number of errors made during practice was related to the amount of learning, and the degree of conscious monitoring of the movement. Only @entity1 with relatively good working memory capacity and a poor initial performance showed a rudimentary form of (most likely, explicit) learning. These new findings on the effect of the amount of practice errors on motor learning in @entity1 of @entity306 are important for designing interventions for @entity1 and adolescents with @entity306 .

title: The influence of errors during practice on motor learning in young individuals with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'children']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['intellectual disabilities']

entities_list: @entity306 :: ('MESH:D002547', 'Disease') :: ['cerebral palsy', 'CP']

answer: @entity306 :: (MESH:D002547,Disease) :: ['cerebral palsy']


abstract: A @entity2909 rarely causes @entity5642 ( @entity5642 ). In the present report, we describe a case of @entity5642 caused by @entity2909 . A 36-year-old nulliparous @entity1 presented with @entity931 and a lower abdominal mass. On magnetic resonance imaging, we detected a 14   cm uterine @entity5 , which was suspected to be a @entity242 . Blood tests at the preoperative examination indicated platelet count of 9.6   10(4)/ L, fibrin degradation product level of 107.1    g/mL (normal value, 0-5.0    g/mL), and @entity2002 level of 54   mg/dL (normal value, 129-271   mg/dL). Based on these findings, we diagnosed the @entity1 with @entity5642 . The @entity1 was treated with @entity12093 and fresh frozen plasma, but the @entity5642 did not show any improvement. Subsequently, a hysterectomy was performed, after which the @entity5642 improved. Clinicopathological findings indicated the presence of a @entity2909 with multiple vessels containing thromboemboli, and suggested that the @entity5642 was caused by the @entity2909 . Therefore, it is essential to consider that that a @entity2909 may be a cause of @entity5642 .

title: Disseminated intravascular coagulopathy caused by XXXX with @entity242 -like findings on magnetic resonance imaging.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity12093 :: ('MESH:C032855', 'Chemical') :: ['nafamostat mesilate']

entities_list: @entity5642 :: ('MESH:D004211', 'Disease') :: ['DIC', 'disseminated intravascular coagulopathy']

entities_list: @entity931 :: ('MESH:D008595', 'Disease') :: ['hypermenorrhea']

entities_list: @entity2909 :: ('MESH:D007889', 'Disease') :: ['benign leiomyoma', 'leiomyoma']

answer: @entity2909 :: (MESH:D007889,Disease) :: ['uterine leiomyoma']


abstract: OBJECTIVE: To compare the effects of @entity3403 , @entity9886 , and their combination in the prevention of @entity5707 ( @entity5707 ) after @entity583 ( @entity583 ) in @entity35 . METHODS: Twenty-four hours after the induction of @entity583 , the 254 survival @entity35 were randomly assigned to the following groups and received drug treatment: (1) @entity583 controls (n=64), (2) @entity3403 (30 mg x kg(-1) x d(-1), n = 63), (3) @entity9886 (10 mg x kg(-1) x d(-1), n = 62), and (4) combination @entity3403 and @entity9886 (30 and 10 mg x kg(-1) x d(-1) respectively, n = 65) treatment groups. Also, sham operated @entity35 (n = 30) were selected randomly. Each group was further divided into three subgroups of 1, 2, and 4 weeks of treatment. After the completion of treatment, hemodynamic studies were performed. Then, the heart of @entity35 was fixed and analyzed pathologically. RESULTS: Exclusive of the dead @entity35 and the hearts with the @entity583 size < 35% or > 50%, complete experimental data were obtained in 157 @entity35 . Besides sham operated @entity35 , there was no significant difference in @entity583 sizes among the 12 subgroups of @entity583 control and drug treatment groups (P> 0.05). Compared with sham operated @entity35 , left ventricular end diastolic pressure (LVEDP) and left ventricular absolute weight and relative weight (LVAW and LVRW) were significantly increased in 1, 2, and 4 week subgroups of @entity583 controls (P < 0.05, P < 0.01, and P < 0.001, respectively), with LVEDP elevated more significantly in 4 week than in 1 and 2 week subgroups (P < 0.01); whereas the maximum rising and dropping rate of left ventricular pressure (+/-dp/dt) and its corrected value by left ventricular systolic pressure (+/-dp/dt/LVSP) were all significantly decreased only at 4 week subgroup of @entity583 controls (P < 0.001). Compared with @entity583 controls group, LVEDP was significantly decreased in all 1, 2, and 4 week subgroups of the three treatment groups (P < 0.05, P < 0.01, and P < 0.001, respectively); LVAW and LVRW were significantly decreased in 2 and 4 week subgroups of @entity9886 and combination groups (P < 0.05, P < 0.01, P < 0.001, respectively), and in only 4 week subgroup in @entity3403 (P < 0.05, P < 0.01, and P < 0.001, respectively); whereas the maximum dropping rate of left ventricular pressure and the corrected value of left ventricular pressure rising and dropping rate were significantly increased only in 4 week subgroups of all three treatment groups (P < 0.05, P < 0.01, respectively). There is no significant difference in all indices above among the three treatment groups at all three time points (P > 0.05). CONCLUSION: It is indicated that @entity3403 can prevent @entity5707 and improve its systolic and diastolic function after @entity583 in @entity35 , with the equivalent effect to that of @entity9886 . There seems no additive effect when the two drugs are used in combination.

title: [Comparison of XXXX , @entity9886 , and their combination in the prevention of post-infarction remodeling in @entity35 ].

entities_list: @entity3403 :: ('MESH:D004318', 'Chemical') :: ['doxycycline']

entities_list: @entity9886 :: ('MESH:D019808', 'Chemical') :: ['losartan']

entities_list: @entity5707 :: ('MESH:D020257', 'Disease') :: ['LVRM', 'left ventricular remodeling']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'myocardial infarction', 'acute myocardial infarction']

answer: @entity3403 :: (MESH:D004318,Chemical) :: ['doxycycline']


abstract: OBJECTIVE: To evaluate the feasibility of quantifying low temperature radiofrequency catheter ablation (RFCA) lesions using a phased array intracardiac echocardiography (ICE) catheter--with better tissue penetration and in a deflectable device-in the @entity235 model. INTERVENTION: Low temperature radiofrequency (RF) energy (50-60 degrees C at up to 40 W) was delivered to the left ventricle in 11 beagles for 60 seconds, using an 8 French catheter with a deflectable tip and a 4 mm distal electrode. MAIN OUTCOME MEASURES: Comparison of the width and depth of @entity75 measured by ICE with pathological findings. RESULTS: 33 RF energies were delivered in 11 @entity235 . 31 lesions (94%) were confirmed at necropsy. 27 of 31 ablation lesions (87%) were detected by ICE. The mean (SD) width and depth of the ICE detected lesions were 10.4 (2.6) mm and 5.7 (1.9) mm, respectively. Pathological findings showed that @entity75 consisted of inner and outer layers. Macroscopically, the mean (SD) width and depth of the inner layers were 7.6 (2.3) mm and 3.6 (1.2) mm and those for the whole layers were 10.0 (2.8) mm and 5.3 (1.5) mm, respectively. Microscopically, the inner and outer layers corresponded to @entity39 and oedematous areas, respectively. The ICE detected lesion size had better correlation with the pathological measurements of the whole layers in width (r = 0.911) and in depth (r = 0.756). CONCLUSION: The real time evaluation of RFCA lesion size using the phased array ICE is feasible, even with a low temperature RF application. However, ICE slightly overestimates RFCA lesion size compared with pathological @entity39 size.

title: Real time quantification of low temperature radiofrequency ablation lesion size using phased array intracardiac echocardiography in the XXXX model: comparison of two dimensional images with pathological lesion characteristics.

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['RFCA lesions']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrotic', 'necrotic lesion']

answer: @entity235 :: (9615,Species) :: ['canine']


abstract: Developmental age @entity11810 is a rare @entity209 , which pathomechanism is different from @entity170 . Its etiology still remains unknown. An onset of the disease is rapid, affecting previously healthy @entity1 of both sexes aged 3.5-15. A rapid loss of bone mass is especially remarkable. Clinical picture of the disease includes @entity158 localised initially in feet, then in thoraco-lumbar section of the vertebral column, gradually progressive @entity85 axes of limbs, gait pathology and progressive depletion of a lower limb muscle strength. The onset of the disease is non-specific. Diagnosis is possible on the basis of roentgen imaging depicting rarefaction of cancellous layer of the bone, numerous infractions of long bones and typical for @entity85 with reduction of their vertical dimension. Current research presents two-staged method of rehabilitation applied in developmental age @entity170 . The main principle of treatment is based on increasing axial load of lower limbs in antigravitational position causing joint surfaces to be pushed together. Final stage of rehabilitation includes interval training on a moving track.

title: [Developmental age XXXX --diagnostics and rehabilitation].

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity11810 :: ('MESH:C537700', 'Disease') :: ['idiopathic osteoporosis']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['involutional osteoporosis', 'osteoporosis']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disease']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['osteoporotic deformation of vertebral shafts', 'deformation of the longitudinal']

answer: @entity11810 :: (MESH:C537700,Disease) :: ['idiopathic osteoporosis']


abstract: BACKGROUND: So far, most of the surgical techniques for @entity9168 are two-stage procedures. In this study, we investigated a modified one-stage procedure to reduce the suffering of @entity1 . METHODS: From 2003 to 2005, we adopted an one-stage technique combining @entity1736 correction with medial canthoplasty in 16 @entity1 with @entity9168 (10 male, 6 female; aged from 6 to 21). All the @entity1 had bilateral severe @entity1736 , epicanthus inversus, and flat dorsum nasi. The movement of the upper lid was 0 to 3 mm, vertical length of the eye fissure 2 to 4 mm, horizontal length 13 to 22 mm, and the distance between the eyes was 35 to 39 mm. The @entity1 were followed up for one half to 2 years after the operation. RESULTS: In all the @entity1 , after the operation, the horizontal length of the eyelid > 25 mm, the vertical length > 6 mm. and the distance between the eyes < 35 mm. The appearance of their double eyelids was satisfying. CONCLUSION: The modified one-stage technique combining @entity1736 correction with medial canthoplasty can achieve favorable outcomes for @entity1 with @entity9168 .

title: Surgical strategy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity9168 :: ('MESH:C562419', 'Disease') :: ['congenital blepharophimosis syndrome']

entities_list: @entity1736 :: ('MESH:D001763', 'Disease') :: ['blepharoptosis']

answer: @entity9168 :: (MESH:C562419,Disease) :: ['congenital blepharophimosis syndrome']


abstract: The molecular basis for blast transformation of @entity1860 ( @entity1860 ) remains poorly understood. Cytogenetic alterations associated with @entity1860 have previously been extensively studied by conventional G-banding analysis. However the complexity of some @entity2008 or poor chromosome morphology or both has exceeded the resolution of G-banding analysis in a significant proportion of @entity1860 cases, and complex chromosome rearrangements have remained unidentified. In this study, comparative genomic hybridization (CGH) was used to elucidate genome imbalances in chronic phase or blast crisis samples or both from 12 @entity1860 @entity1 . CGH and G-banding results were compared, and discrepancies were further clarified by using multipaint chromosome analysis and locus-specific DNA probes. No imbalances were detected in the 4 early disease phase samples studied. @entity9638 samples were analyzed by G-banding and CGH, and the commonest genomic abnormality detected was overrepresentation of the long arm of chromosome 8, which was detected in 5 @entity1 . This overrepresentation was attributable to trisomy 8 in 4 @entity1 , whereas amplification of the entire long arm of chromosome 8 was detected in 1 @entity1 . The formation of isochromosomes of the long arm of chromosome 8 was observed as a mechanism for gene amplification in this @entity1 . Additional material originating from chromosome 8 was also observed intercalated into three marker chromosomes in peripheral blood metaphase spreads from this @entity1 . These markers may further define areas on chromosome 8 that harbor oncogenes implicated in transformation of @entity1860 .

title: Comparative analysis of G-banding, chromosome painting, locus-specific fluorescence in situ hybridization, and comparative genomic hybridization in XXXX blast crisis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2008 :: ('MESH:D002869', 'Disease') :: ['chromosome abnormalities']

entities_list: @entity9638 :: ('MESH:D001752', 'Disease') :: ['Eleven blast crisis']

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'CML blast crisis', 'chronic myeloid leukemia']

answer: @entity1860 :: (MESH:D015464,Disease) :: ['chronic myeloid leukemia']


abstract: OBJECTIVE: To determine clinical and EEG features that might help identify @entity1 with @entity302 harboring small, intrinsically epileptogenic, surgically treatable, @entity19312 ( @entity19312 ). METHODS: Retrospective review of clinical records, EEG, MRI, and histopathology in 32 @entity1 with @entity302 and MRI-positive (72% 3.0 tesla), pathologically proven (type 2B @entity6795 ) @entity19312 operated at our centers during 2005-2013. RESULTS: Localization of @entity19312 was frontal in 19, insula in 5, parietal in 5, and temporal in 3, on the convexity or interhemispheric surfaces. @entity19312 were missed on initial MRI at our centers in 22% of @entity1 . @entity1 presented with focal @entity410 during infancy in 9, preschool years in 15, and school years in 8 (median age 5 years). @entity410 were stereotyped, predominantly nocturnal, and typically @entity6191 , with semiology referable to the fronto-central or perisylvian regions. @entity410 occurred at high frequency during active periods, but often went into prolonged remission with @entity2049 or @entity3174 . Intellect was normal or borderline, except in @entity1 with @entity410 onset during infancy. Scalp EEG frequently revealed localized interictal epileptiform discharges and ictal rhythms. @entity1 underwent lesionectomy (median age 14 years) guided by electrocorticography and MRI, with prior intracranial EEG monitoring in only one @entity1 . Twenty-eight @entity1 (88%) became @entity410 -free, and 20 discontinued antiepileptic medication (median follow-up 4.1 years). CONCLUSIONS: In @entity1 with cryptogenic @entity1625 , this clinical presentation and course should prompt review of or repeat MRI, looking for a BOSD in the frontal, parietal, or insula cortex. If a BOSD is identified, the @entity1 might be considered for single-stage lesionectomy.

title: The surgically remediable syndrome of XXXX associated with @entity19312 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'Seizures', 'seizures']

entities_list: @entity1625 :: ('MESH:D004828', 'Disease') :: ['focal epilepsy']

entities_list: @entity6795 :: ('MESH:D054220', 'Disease') :: ['cortical dysplasia']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy', 'drug-resistant epilepsy']

entities_list: @entity6191 :: ('MESH:D004829', 'Disease') :: ['nonconvulsive']

entities_list: @entity3174 :: ('MESH:D010672', 'Chemical') :: ['phenytoin']

entities_list: @entity19312 :: ('MESH:C536345', 'Disease') :: ['BOSDs', 'bottom-of-sulcus dysplasias']

entities_list: @entity2049 :: ('MESH:D002220', 'Chemical') :: ['carbamazepine']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: OBJECTIVE: To investigate the role of @entity268 -responsive element modulator-tau (CREMtau), an essential transcription factor for spermatogenesis, in ipsilateral @entity130 after unilateral testicular torsion-detorsion. DESIGN: Controlled experimental study using @entity35 . SETTING: Research laboratory. ANIMAL(S): Twenty adult male @entity35 . INTERVENTION(S): Ten @entity35 in the control group underwent a sham operation of the left testes. Ten @entity35 in the torsion-detorsion group received 1 hour of @entity4115 . Orchiectomy was performed on all @entity35 3 months after detorsion. MAIN OUTCOME MEASURE(S): Testicular spermatogenesis was evaluated by measuring testicular weight, mean seminiferous tubular diameter, number of germ cell layers, and mean testicular biopsy score. The expressions of CREMtau mRNA and protein in testes were detected by reverse transcription-polymerase chain reaction and Western blot, respectively. RESULT(S): Unilateral testicular torsion-detorsion caused significant spermatogenic @entity16 , including reductions in testicular weight, mean seminiferous tubular diameter, number of germ cell layers, and mean testicular biopsy score. In ipsilateral testes with @entity16 , the expressions of CREMtau mRNA and protein were also significantly reduced. CONCLUSION(S): Reduction in testicular CREMtau expression may be one of the mechanisms responsible for impairment of spermatogenesis in ipsilateral testes after unilateral testicular torsion-detorsion.

title: Role of XXXX -responsive element modulator-tau (CREMtau) in ipsilateral @entity130 after unilateral testicular torsion-detorsion.

entities_list: @entity4115 :: ('MESH:D013086', 'Disease') :: ['left testicular torsion']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['spermatogenic damage', 'damage in the ipsilateral testes']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['testicular injury']

answer: @entity268 :: (CHEBI:17489,Chemical) :: ['cAMP']


abstract: BACKGROUND: @entity64 ( @entity64 ) is associated with poor clinical and functional outcomes, and @entity1 are likely to experience @entity64 more than @entity1 . Although stress is related to @entity308 , and @entity1 report greater emotional reactivity to stressful life events, the link between stress and gender is yet to be examined relative to @entity64 . Further, electronic momentary assessment (EMA), a mobile technology, has not been used to assess stressful life events and @entity64 in real time and in the natural environments of daily life. The purpose of the current study was to examine gender differences in the relationship of stress and @entity64 using EMA. METHODS: Individuals admitted to the @entity64 Center at the University of Bordeaux were contacted for participation in a prospective study of symptoms and experiences in daily life using ambulatory monitoring. Forty-three post- @entity64 @entity1 (47% female) completed electronic assessments of life events, perceived stress, and @entity308 (i.e., sad mood, @entity4270 , @entity1295 , concentration difficulties, appetite change, negative thoughts, hopelessness) during their daily life for one week. @entity1 also completed a clinician-administered standardized @entity308 scale at baseline and three-month follow-up. RESULTS: Using EMA, @entity1 responded to 83.7% of the electronic interviews for a total of 1,140 observations across diverse daily life contexts. Stressful events of any degree of negativity were reported at over one-third (37.3%) of all EMA assessments. The severity of @entity308 as assessed in daily life through EMA was greater in @entity1 following @entity64 than in @entity1 . Further, there was a significant association between EMA-assessed @entity308 and daily life stress for @entity1 , but not @entity1 . This association was due primarily to three specific @entity308 : sad mood, @entity1295 , and appetite change. No difference was observed between @entity1 and @entity1 in standardized @entity308 assessments administered during clinic visits at baseline or three-month follow-up. CONCLUSIONS: Greater reactivity to stressful life events and a link between stress reactivity and @entity308 were found in female as compared to male post- @entity64 @entity1 . Gender differences in @entity308 were identified using EMA data collected during daily life as contrasted with the use of a standard assessment during clinic visits. Mobile technologies may help to identify important real-time behaviors and symptoms that are not observable by standard clinical assessments employed at regular clinic visits. Further, future research should examine the overall and gender-specific benefits of stress-based interventions to reduce the risk of @entity64 for adults.    2014 S. Karger AG, Basel.

title: Gender and stress in predicting XXXX following @entity64 .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Patients', 'patients', 'men']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'Stroke', 'Post-stroke depression', 'PSD']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive symptoms', 'depression']

entities_list: @entity4270 :: ('MESH:D059445', 'Disease') :: ['anhedonia']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depressive symptoms']


abstract: BACKGROUND: Although widely practiced for over 80 years, the role of @entity6542 ( @entity6542 ) in pediatric @entity565 treatment is still controversial. We assessed the effects of a 3-year period of subcutaneous administration of a standardized preparation of @entity7130 (D pt) on the respiratory health in a group of asthmatic @entity1 monosensitized to @entity6711 ( @entity6711 ). METHODS: A randomized clinical trial was performed after 1-year run-in period. Fifteen @entity1 receiving @entity6542 for @entity6711 and 14 controls (four drop-outs), matched for age, allergen sensitization, @entity565 severity, lung function, and non-specific bronchial reactivity (BHR), were studied during the 3-year treatment period. During the whole trial, respiratory symptoms, pharmacological and respiratory function parameters were regularly evaluated. Skin prick tests and @entity2710 challenge were performed at the beginning and end of the study. RESULTS: In the @entity6542 group significant improvement in asthmatic symptoms and marked reduction in drug intake was observed. The @entity6542 group also showed a significant decrease in non-specific bronchial BHR. No new sensitivity occurred during the study period in the @entity6542 group only. No major local or systemic side-effects were reported during the study. CONCLUSIONS: Our results confirm that @entity6542 is effective in asthmatic @entity1 sensitive to mites. It is associated with a decrease in BHR and it may prevent the development of new sensitizations in monosensitized subjects.

title: Benefits of immunotherapy with a standardized @entity7130 extract in asthmatic XXXX : a three-year prospective study.

entities_list: @entity6542 :: ('MESH:C562465', 'Disease') :: ['specific immunotherapy', 'SIT']

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity7130 :: ('6956', 'Species') :: ['Dermatophagoides pteronyssinus']

entities_list: @entity2710 :: ('MESH:D016210', 'Chemical') :: ['methacholine']

entities_list: @entity6711 :: ('MESH:D008924', 'Disease') :: ['HDM', 'house dust mite']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: PURPOSE: To review the epidemiology of penetrating @entity4858 and @entity397 presenting to the Royal Adelaide Hospital, South Australia. METHODS: A retrospective case review over a 4-year period. RESULTS: There were 109 penetrated or @entity397 in 105 @entity1 . The average age was 41 years and 80.2% were @entity1 . Over half were from rural areas. The commonest cause of injury was hammering metal followed by motor vehicle accidents. Falls in the elderly were the commenest cause of globe @entity397 . A final visual acuity of 6/12 or better was found in 40% of eyes and no perception of light in 27%. CONCLUSIONS: At the Royal Adelaide Hospital, the predominant referral centre for serious @entity4858 in South Australia, approximately 25 @entity542 are encountered a year. Although the epidemiology of these injuries was found to be similar to those previously reported in Victoria and rural New South Wales, differences were thought to reflect to the ageing population of South Australia. Rupture of an old, healed large-incision @entity231 extraction wound was the commonest cause of @entity397 . An effective preventive strategy to reduce the incidence of severe @entity2194 has yet to be implemented. The concept of a national population-based severe @entity2194 database is considered.

title: Four-year review of XXXX at the Royal Adelaide Hospital.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular trauma']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['open globe injuries']

entities_list: @entity4858 :: ('MESH:D005131', 'Disease') :: ['eye injuries', 'ocular injury']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['ruptures', 'ruptured globes', 'ruptured globe']

answer: @entity4858 :: (MESH:D005131,Disease) :: ['open eye injuries']


abstract: UNASSIGNED: The inhibitory effects demonstrated by activation of cannabinoid receptors (CB) on @entity5 proliferation and migration may also play critical roles in controlling @entity150 ( @entity150 ). CB expression on @entity1 normal and @entity150 specimens was tested by immunohistochemistry. @entity1 @entity150 cells RT4 and RT112 were challenged with CB agonists and assessed for proliferation, apoptosis, and motility. Cellular @entity13740 (SL) constitution and metabolism were evaluated after metabolic labelling. @entity65939 were detected in @entity150 specimens, but only @entity12332 was more expressed in the @entity5 . Both cell lines expressed similar @entity12332 . Exposure to @entity12332 agonists inhibited @entity150 growth, down-modulated @entity584 , induced @entity522 -activation and modified SL metabolism. Baseline SL analysis in cell lines showed differences linked to unique migratory behaviours and cytoskeletal re-arrangements. @entity12332 activation changed the SL composition of more aggressive @entity1 cells by reducing (p   <   0.01) @entity17267 ganglioside (-50        3%) and @entity5595 ( @entity5596 , -40        4%), which ended up to reduction in cell motility (-46        5%) with inhibition of p-SRC. @entity12332 -selective antagonists, gene silencing and an inhibitor of SL biosynthesis partially prevented @entity12332 agonist-induced effects on cell viability and motility. @entity12332 activation led to @entity2367 -mediated @entity150 cell apoptosis independently of SL constitutive composition, which instead was modulated by @entity12332 agonists to reduce cell motility.

title: XXXX cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of @entity13740 metabolism.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumour']

entities_list: @entity13740 :: ('MESH:D013107', 'Chemical') :: ['sphingolipids']

entities_list: @entity2367 :: ('CHEBI:17761', 'Chemical') :: ['ceramide']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['BC', 'bladder cancer']

entities_list: @entity5595 :: ('MESH:C060506', 'Chemical') :: ['sphingosine 1-phosphate']

answer: @entity150 :: (MESH:D001749,Disease) :: ['Bladder cancer']


abstract: INTRODUCTION: Whitlow is an infection of a finger or around the fingernails, generally caused by bacterium. However, in rare cases, it may also be caused by the herpes simplex virus. As @entity10926 is not seen often, it may go under-recognised or be mistaken for a different kind of infection of the finger. Delayed recognition and/or treatment puts @entity1 at risk of complications ranging from superinfection to @entity10926 . CASE PRESENTATION: A 23-year-old Caucasian @entity1 with no medical history was referred by his primary care physician because of erythema and swelling of the little finger of his left hand. The primary care physician had already treated him with the oral antibiotic Augmentin   (amoxicillin-clavulanic acid) and incision of the finger, but this had not resolved his complaints. He had multiple vesicles on the finger, which led to the diagnosis of @entity10926 , which we confirmed by polymerase chain reaction testing. All cutaneous @entity2402 after treatment. CONCLUSIONS: Whitlow is rarely caused by the herpes simplex virus, but this disease requires a @entity514 recognition and treatment to prevent complications. This case serves to emphasise that not all whitlow is caused by a @entity2348 , and that it is important to differentiate between herpetic and bacterial whitlow, as these diseases require a different treatment.

title: A XXXX with an infected finger: a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity2402 :: ('MESH:D010015', 'Disease') :: ['abnormalities disappeared']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infection']

entities_list: @entity10926 :: ('MESH:D020803', 'Disease') :: ['herpetic whitlow', 'herpetic encephalitis']

answer: @entity1 :: (9606,Species) :: ['man']


abstract: Expression of the @entity1722 gene product and the @entity470 ( @entity470 ) was investigated in 54 cases of @entity1 @entity150 immunohistologically and by Western blot analysis. For detection of the @entity1722 product, two specific antibodies, a rabbit polyclonal antibody directed to the intracellular domain and a murine monoclonal antibody recognizing an epitope in the extracellular domain, were used. Seventeen cases of @entity150 were stained by the anti- @entity1722 polyclonal antibody, while 20 cases were stained by the monoclonal antibody, with good correlation on both stainings (p less than 0.01). There were four @entity1722 positive cases in 26 G1 @entity5 , four in 15 G2 @entity5 , and nine in 13 G3 @entity5 . There were also eight @entity1722 positive cases in nine muscle-invasive @entity5 , nine of 45 superficial @entity5 , four of five with lymph node @entity3 , and seven of 14 without @entity3 , as revealed by staining with the polyclonal antibody. Thus, the @entity1722 gene product was more frequently expressed in high grade @entity5 (p less than 0.01), in high stage @entity5 (p less than 0.01), and nodal @entity3 (N.S. by Chi-square test). Twenty-two of the 54 @entity5 were stained by an anti- @entity470 monoclonal antibody, 528 IgG. The expression of @entity470 was independent of histological grading, @entity5 stage, and nodal status, and no correlation was observed between expression of the @entity1722 product and @entity470 . The @entity1722 product may be applicable as a @entity5 marker for evaluation of malignant potential, invasiveness, and probably metastatic potential of @entity1 @entity150 .

title: Expression of XXXX gene product in @entity150 .

entities_list: @entity470 :: ('1956', 'Gene') :: ['epidermal growth factor receptor', 'EGF-R']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastatic tumors']

answer: @entity1722 :: (2064,Gene) :: ['c-erbB-2']


abstract: BACKGROUND: Results from small randomised trials on @entity440 in the treatment of @entity157 ( @entity157 ) are conflicting. We studied whether the addition of @entity440 to best supportive care prolongs survival of @entity1 with @entity157 . METHODS: @entity1 with any stage of @entity157 were eligible, irrespective of locoregional treatment. Randomisation was centralised, with a minimisation procedure accounting for centre, evidence of disease, and time from diagnosis. @entity1 were randomly allocated best supportive care alone or in addition to @entity440 . @entity440 was given orally, 40 mg per day, from randomisation until @entity204 . RESULTS: 496 @entity1 from 30 institutions were randomly allocated treatment from January, 1995, to January, 1997. Information was available for 477 @entity1 . By Sept 15, 1997, 119 (50%) of 240 and 130 (55%) of 237 @entity1 had died in the control and @entity440 arms, respectively. Median survival was 16 months and 15 months (p=0.54), respectively. No differences were found within subgroups defined by prognostic variables. Relative hazard of @entity204 for @entity1 receiving @entity440 was 1.07 (95% CI 0.83-1.39). INTERPRETATION: Our findings show that @entity440 is not effective in prolonging survival of @entity1 with @entity157 .

title: @entity440 in treatment of XXXX : a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme)

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen', 'Tamoxifen']

answer: @entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']


abstract: Several malformed individuals were presented at the World Exhibition in Antwerp in 1894. Among them was Mrs. Alice Vance from Mount Pleasant, Texas, with @entity4218 , and Mr. Eugen Berry, who had asymmetrical, monstrous enlargement and @entity41163 of the feet, i.e., @entity795 . After the World Exhibition Mrs. Vance presented herself to the public in Castan's Panopticon imitating a bear. She became famous under the stage name "Das B  renweib" ("the bear-like @entity1 ") and was examined by several German clinicians, and her @entity600 were considered to be of high scientific interest. Mrs. Vance had mesomelic dwarfism and her mother was known to have similar @entity600 . Her @entity4218 were generally considered a unique congenital condition those days, and the diagnosis of "a maternally inherited @entity600 of the forearms and the shanks" [Daffner 1898: Munch Med Wochenschr 25:782] was made. Virchow [1897: Verh Berl Ges Ethnol Urgeschichte 29:624], feeling attacked by a daily newspaper stating that the physicians as well as the police of Berlin had missed the diagnosis of an "English disease," eventually exercised his authority and diagnosed Alice Vance as a "phocomelic." Clearly, she was not a phocomelic according to past and current definition of this term. Thus, from a historical point of view, the story illustrates how pressure from the daily press altered the definition of an up-to-then precisely defined medical term for decades. According to the clinical data and an X-ray report available from the literature, Alice Vance had a dominantly inherited type of mesomelic dwarfism. We propose the diagnosis of @entity64257 .

title: Alice Vance ("Das B  renweib"): a historical case of XXXX .

entities_list: @entity795 :: ('MESH:D016715', 'Disease') :: ['Proteus syndrome']

entities_list: @entity64257 :: ('MESH:C536120', 'Disease') :: ['Nievergelt syndrome']

entities_list: @entity4218 :: ('MESH:D017880', 'Disease') :: ['limb deficiencies', 'congenital limb defects']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations', 'malformation']

entities_list: @entity41163 :: ('MESH:C562546', 'Disease') :: ['macrodactyly']

answer: @entity64257 :: (MESH:C536120,Disease) :: ['Nievergelt syndrome']


abstract: The Fas receptor is a potentially valuable therapeutic target in @entity5 treatment. However, the clinical application of antibodies directed to this target is hindered by their serious side effects in vivo, including liver @entity137 . One murine monoclonal antibody, mHFE7A, binds both to @entity1 Fas and @entity19 Fas, without inducing any obvious side effects. However, the potential therapeutic effects of mHFE7A are unclear in @entity1 @entity5 cells or @entity5 . Here, we determined whether mHFE7A could induce apoptosis in vitro, and assessed its effects on major apoptotic pathways in a @entity1 @entity320 cell line, MMN9. We also investigated its anti- @entity5 effects on transplanted @entity320 in BALB/c @entity19 . Treatment of mHFE7A cross-linking with Ig induced cell death similar to @entity10762 treatment. Apoptosis induced by mHFE7A was defined by @entity5956 DNA staining and DNA fragmentation assay. Furthermore, mHFE7A-mediated apoptosis was dependent on activation of a caspase signaling cascade involving @entity61320 . Administration of mHFE7A also delayed the growth of @entity320 xenografts. Thus, we provide the first evidence that the murine anti-Fas monoclonal antibody, mHFE7A, induces apoptosis of @entity1 @entity320 cells in vitro and is anti-tumorigenic in vivo.

title: mHFE7A, a newly identified monoclonal antibody to Fas, induces apoptosis in @entity1 @entity320 cells in vitro and delays the growth of XXXX xenotransplants.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumors']

entities_list: @entity19 :: ('10090', 'Species') :: ['nude mice', 'murine']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'melanoma MMN9 tumors', 'malignant melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['melanoma']


abstract: BACKGROUND: There is a burgeoning literature examining perceptions of being defeated or trapped in different @entity146 . The disorders most frequently examined to date are @entity308 , @entity148 , @entity1005 ( @entity1005 ), and suicidality. AIMS: To quantify the size and consistency of perceptions of defeat and entrapment in @entity308 , @entity148 , @entity1005 and suicidality, test for differences across @entity146 , and examine potential moderators and publication bias. METHOD: Random-effects meta-analyses based on Pearson's correlation coefficient r. RESULTS: Forty studies were included in the meta-analysis (n=10,072). Perceptions of defeat and entrapment were strong (around r=0.60) and similar in size across all four @entity146 . Perceptions of defeat were particularly strong in @entity308 (r=0.73). There was no between-study heterogeneity; therefore moderator analyses were conducted in an exploratory fashion. There was no evidence of publication bias. LIMITATIONS: Analyses were cross-sectional, which precludes establishing temporal precedence or causality. Some of the meta-analyses were based on relatively small numbers of effect sizes, which may limit their generalisability. CONCLUSIONS: Perceptions of defeat and entrapment are clinically important in @entity308 , @entity148 , @entity1005 , and suicidality. Similar-sized, strong relationships across four different @entity146 could suggest that perceptions of defeat and entrapment are transdiagnostic constructs. The results suggest that clinicians and researchers need to become more aware of perceptions of defeat and entrapment.

title: A meta-analysis of perceptions of defeat and entrapment in @entity308 , XXXX , @entity1005 , and suicidality.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety problems']

entities_list: @entity1005 :: ('MESH:D013313', 'Disease') :: ['posttraumatic stress disorder', 'PTSD']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disorders']

answer: @entity148 :: (MESH:D001008,Disease) :: ['anxiety problems']


abstract: The National @entity165 Education Program defines the @entity209 as three or more of five abnormalities: waist circumference of >40 in (102 cm) for @entity1 or >35 in (88 cm) for @entity1 , @entity412 level of > or =150 mg/dL, high-density lipoprotein @entity165 of <40 mg/dL in @entity1 or <50 mg/dL in @entity1 , blood pressure of > or =130 or > or =85 mm Hg, and fasting @entity413 of > or =110 mg/dL. It is related to insulin resistance, but the two terms are not synonymous. Both are associated strongly with @entity28 . The @entity209 is important as an indicator of increased risk of @entity65 ( @entity65 ) in @entity1 with and without clinical @entity65 . The @entity65 risk of the @entity209 is greater than that conferred by any single @entity65 risk factor. Since risk factors tend to cluster, if one component of the @entity209 is present, one should assess for other risk factors. The @entity209 is also predictive of new-onset @entity164 2 @entity6 . Early diagnosis provides justification for measures that can improve components of the syndrome and reduce @entity65 risk. The management strategy for @entity209 focuses on overall @entity65 risk rather than single risk factors; effective therapy includes priority for @entity353 and increased physical activity. Pharmacotherapy is typically needed for control of @entity101 , @entity49 , and increased levels of blood @entity413 and @entity1674 .

title: The XXXX : recognition and management.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight reduction']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['high blood pressure']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['hypercoagulability']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol', 'cholesterol']

answer: @entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']


abstract: Whether intensive glycemic control can reduce incidence of @entity6 or other @entity532 remains undefined. In this meta-analysis, we assessed the effects of intensive versus conventional glycemic control in @entity2194 in @entity1 with @entity164 2 @entity6 . A systematic literature search of PubMed, Web of Knowledge, and Scopus (until December 12, 2013) was conducted. Randomized controlled trials which compared intensive glycemic control with conventional glycemic control in ocular events in @entity1 with @entity164 2 @entity6 were included. Random-effects models were used to measure the pooled odds ratio (OR) with 95  % confidence interval (CI). Seven trials involving 32,523 @entity1 were included. Intensive glycemic control reduced the risks of @entity2479 or vitrectomy (OR 0.86; 95  % CI 0.75-0.98), @entity1103 (OR 0.65; 95  % CI 0.43-0.99), and progression of @entity989 (OR 0.69; 95  % CI 0.55-0.87). No significant risk reduction was shown in incidence of @entity989 (OR 0.67; 95  % CI 0.26-1.73), @entity231 surgery (OR 0.88; 95  % CI 0.76-1.03), or severe @entity1018 or @entity1939 (OR 0.99; 95  % CI 0.86-1.13). Intensive glycemic control reduces the risk of most @entity989 -related events. But no beneficial effect was shown in ocular endpoint as severe @entity1018 or @entity1939 .

title: Effects of intensive glycemic control in @entity2194 in @entity1 with XXXX 2 @entity6 : a meta-analysis of randomized clinical trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1018 :: ('MESH:D054062', 'Disease') :: ['loss of vision']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular complications']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'diabetic retinopathy']

entities_list: @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal photocoagulation']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['diabetes-associated ocular complications']

entities_list: @entity1103 :: ('MESH:D008269', 'Disease') :: ['macular edema']

entities_list: @entity1939 :: ('MESH:D001766', 'Disease') :: ['blindness']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy']

answer: @entity164 :: (MESH:D017827,Disease) :: ['type']


abstract: There is interest in developing prolonged duration local anesthesics. Here we examine whether @entity1022 ( @entity4524 ) can be used to prolong the block from @entity1341 microspheres with and without @entity619 . @entity35 received sciatic nerve blocks with 75 mg of microspheres containing 0.05% (w/w) @entity4524 , 50% (w/w) @entity1341 and/or 0.05% (w/w) @entity619 . 0.1% (w/w) @entity4524 microspheres were also tested. The carrier fluid contained 1:100,000 epinephrine. Nociceptive and motor blockade of the hindpaw were quantified. Nerves and adjacent muscles were harvested 2 weeks after injection for histological assessment by light microscopy. The median nociceptive block duration in hours from the microsphere groups were: @entity1341 =6.2, 0.05% @entity4524 =0, @entity1341 + @entity4524 =35.3, @entity1341 + @entity619 =31.3, @entity4524 + @entity619 =8.1, @entity4524 + @entity1341 + @entity619 =221.7. Some animals receiving particles containing 0.05% @entity4524 had deficits in the uninjected extremity; all animals receiving 0.1% (w/w) @entity4524 particles died. Pockets of particles were associated with localized inflammation, and all samples showed some evidence of myotoxicity in the vicinity of the injection. The nerves themselves appeared intact. In summary, coencapsulation of @entity4524 in controlled release devices containing @entity1341 and @entity619 resulted in @entity1162 . As formulated here, this preparation had a narrow margin of safety. While the myotoxicity appears consistent with the well-known reversible myotoxicity associated with local anesthetics, its long-term significance remains to be established.

title: Prolonged duration local anesthesia from XXXX -enhanced local anesthetic microspheres.

entities_list: @entity1022 :: ('MESH:D013779', 'Chemical') :: ['tetrodotoxin']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['very prolonged nerve blocks']

answer: @entity1022 :: (MESH:D013779,Chemical) :: ['tetrodotoxin']


abstract: BACKGROUND: Quantitative real time reverse transcription PCR (qRT-PCR) is one of the most important techniques for gene-expression analysis in molecular based studies. Selecting a proper internal control gene for normalizing data is a crucial step in gene expression analysis via this method. The expression levels of reference genes should be remained constant among cells in different tissues. However, it seems that the location of cells in different tissues might influence their expression. The purpose of this study was to determine whether the source of mesenchymal stem cells (MSCs) has any effect on expression level of three common reference genes ( @entity60251 , b-actin and b2-microglobulin) in @entity1641 marrow- and adipose- derived undifferentiated MSCs and consequently their reliability for comparative qRT-PCR. MATERIALS AND METHODS: @entity1386 ( @entity1386 ) and bone marrow (BM) samples were harvested from 3 mares. MSCs were isolated and cultured until passage 3 (P3). Total RNA of P3 cells was extracted for cDNA synthesis. The generated cDNAs were analyzed by quantitative real-time PCR. The PCR reactions were ended with a melting curve analysis to verify the specificity of amplicon. RESULTS: The expression levels of @entity60251 were significantly different between @entity1386 - and BM- derived MSCs (p   <   0.05). Differences in expression level of b-actin (P   <   0.001) and @entity60252 (P   <   0.006.) between MSCs derived from @entity1386 and BM were substantially higher than @entity60251 . In addition, the fold change in expression levels of @entity60251 , b-actin and @entity60252 in @entity1386 -derived MSCs compared to BM-derived MSCs were 2.38, 6.76 and 7.76, respectively. CONCLUSION: This study demonstrated that @entity60251 and especially b-actin and @entity60252 express in different levels in @entity1641 @entity1386 - and BM- derived MSCs. Thus they cannot be considered as reliable reference genes for comparative quantitative gene expression analysis in MSCs derived from @entity1641 bone marrow and adipose tissue.

title: @entity60251 , b-actin and b2-microglobulin, as three common reference genes, are not reliable for gene expression studies in XXXX adipose- and marrow-derived mesenchymal stem cells.

entities_list: @entity1386 :: ('MESH:D018205', 'Disease') :: ['AT', 'Adipose tissue']

answer: @entity1641 :: (9796,Species) :: ['equine']


abstract: 14 @entity1 with obstructive @entity3893 were treated with microsurgical vasovasostomy or epididymovasostomy. A total of 11 @entity1 underwent 2-layer vasovasostomy, 6 cases following bilateral vasectomy and 5 cases suffering from bilateral vasal disruption by inguinal herniorrhaphy. 3 @entity1 underwent end-to-end epididymovasostomy with Silber's specific tubule technique following @entity3892 . After the operation, fertility was restored in 6 of 14 cases. The recovered sperm density was greater than 20 x 10 6/ml and sperm motility exceeded 50%. Pregnancy was achieved in 1 case following inguinal herniorrhaphy. Preoperative testicular biopsies carried out in 11 cases disclosed slight deterioration of spermatogenesis. Johnsen's mean score was 8.20 +or- 0.38 (mean +or- S.D.). The mean scores of the biopsies obtained from the cases obstructed for more than 20 years were significantly lower than those with less than a 20-year time period. After inguinal herniorrhaphy, reanastomosis of the vas deferens was difficult in order to restore fertility. This was due to the presence of @entity12108 , or the absence of sperm @entity738 at the vasectomy site. Epididymovasostomy restored fertility in 67% of the cases. The specific tubule technique was the most effective in the management of such pathological conditions. (author's modified)

title: [Clinical experience of XXXX ].

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granuloma']

entities_list: @entity3892 :: ('MESH:D004823', 'Disease') :: ['bilateral epididymitis']

entities_list: @entity12108 :: ('MESH:C535984', 'Disease') :: ['longterm obstruction, defects in the vas deferens']

entities_list: @entity3893 :: ('MESH:D053713', 'Disease') :: ['azoospermia']

answer: @entity3893 :: (MESH:D053713,Disease) :: ['epididymovasostomy and vasovasostomy for obstructive azoospermia']


abstract: OBJECTIVE: To demonstrate the survival impact of intraoperative @entity5 rupture in @entity1 with @entity5 (CCC) of the ovary. METHODS: A total of 193 @entity1 with stage I CCC of the ovary who had undergone a complete staging operation followed by >= three cycles of adjuvant @entity902 -based chemotherapy, were retrospectively reviewed. Survival analysis was performed and compared between three stage groups: IA/IB, @entity32644 , and @entity15539 /IC3. RESULTS: There were 70, 51, and 72 @entity1 with @entity43 in stages IA/IB, @entity32644 , and @entity15539 /IC3, respectively. Intraoperative @entity5 rupture occurred in 69 (35.8%) @entity1 . Gross endometriosis (p=0.020) and significant peritumoral adhesion (p<0.001) were associated with intraoperative @entity5 rupture. However, neither laparoscopic approach nor large @entity5 size >10cm were associated with intraoperative @entity5 rupture. @entity1 with stage @entity15539 /IC3 compared to those with stage @entity32644 , had poorer progression-free survival (PFS) (5-year PFS, 68.5% versus 91.7%; p=0.010) and @entity1349 ( @entity1349 ) (5-year @entity1349 , 81.1% versus 95.4%; p=0.027). However, there was no significant difference between @entity1 with stages IA/IB and @entity32644 CCC in PFS (5-year PFS 88.8% versus 91.7%; p=0.291) and @entity1349 (5-year @entity1349 94.6% versus 95.4%; p=0.444). Stage @entity15539 /IC3 was the only independent poor prognostic factor for @entity1349 (hazard ratio, 3.50; 95% confidence interval, 1.31 to 9.36). CONCLUSION: Surgical spillage of @entity5 cells does not appear to have a negative impact on survival outcomes of @entity1 with @entity43 who received >= three cycles of adjuvant @entity902 -based chemotherapy.

title: The clinical value of surgeons' efforts of preventing intraoperative @entity5 rupture in XXXX of the ovary: A Korean multicenter study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['stage I ovarian CCC', 'ovarian CCC']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'stage I clear cell carcinoma']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity5 :: (MESH:D009369,Disease) :: ['stage I clear cell carcinoma']


abstract: @entity842 (NO), a short-lived gaseous free radical, synthesized from @entity534 by NO synthases (NOS), is a potent mediator of biologic responses involved in the pathogenesis of @entity792 , such as @entity1252 ( @entity1252 ) and @entity309 ( @entity309 ). Most biological necessary NO is produced by the family of three NOS. To date, several functionally relevant genetic polymorphisms in the @entity9554 gene have been associated with various vascular, infectious and @entity792 . To our knowledge, no study has explored these polymorphisms for both @entity1252 and @entity309 in the same population. The objective of this study was to investigate the influence of the @entity9554 gene intron 4 a/b VNTR polymorphism (a 27-base-pair tandem repeat-based polymorphism) on susceptibility to @entity1252 and @entity309 in @entity1 living in the island of Crete, a genetically homogeneous population. A group of 145 healthy subjects and 190 @entity1252 @entity1 were included in this study. Similarly, a second group of 235 healthy controls and 202 @entity309 @entity1 were analysed. In both cases, @entity1 and controls were sex- and age-matched. Herein we report that the presence of a/b genotype of the @entity9554 gene may act as a risk factor not for the presence of @entity1252 but for the development of @entity631 (OR 2.71, 95% CI: 1.4-5.2), while it may be a susceptibility gene for @entity309 (OR: 2.005, 95% CI: 1.31-3.07). Thus, in our population, the a/b genotype of the @entity9554 gene represents a severity rather than a susceptibility genotype for @entity1252 .

title: Association of the @entity842 synthase ( XXXX ) gene polymorphism with increased risk for both lupus glomerulonephritis and @entity309 in a single genetically homogeneous population.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus']

entities_list: @entity534 :: ('CHEBI:16467', 'Chemical') :: ['L-arginine']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['Nitric oxide']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune rheumatic diseases', 'autoimmune diseases']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity9554 :: (4846,Gene) :: ['eNOS']


abstract: OBJECTIVE: Collecting duct @entity703 is a rare and @entity1358 with @entity5 -specific survival. We reviewed our series of collecting duct @entity5 retrospectively. METHODS/RESULTS: We performed a retrospective analysis of the collecting duct @entity703 treated in our unit between January 2007 and December 2012. The variables analysed were: age, gender, reason for consultation, side affected, @entity1281 score according to anaesthetic risk, surgical treatment, @entity5 size, Fuhrman grade, @entity3 , @entity2802 staging (2009 classification), adjuvant treatment and survival time. Four collecting duct @entity189 were identified. Mean @entity1 age was 61 years. @entity9528 and @entity615 were the most frequent reasons for consultation (75%), followed by @entity811 . The surgical treatment was laparoscopic radical nephrectomy in 100% of the cases, with lymphadenectomy in 2 @entity1 due to @entity1600 detected on imaging studies. The 4 @entity1 were initially treated with @entity13850 as adjuvant therapy with no response. Two @entity1 were given second-line treatment with @entity2240 without any response. All 4 @entity1 died from their disease with a mean survival of 9.5 months (rang: 4-15 months). CONCLUSIONS: Collecting duct @entity703 is a rare and aggressive @entity703 . Long-term survival rate is low, because the only potentially curative treatment seems to be surgery if it is performed in @entity1 with @entity5 .

title: Collecting duct XXXX . A contribution of 4 new cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']

entities_list: @entity13850 :: ('MESH:C401859', 'Chemical') :: ['temsirolimus']

entities_list: @entity2240 :: ('MESH:C473478', 'Chemical') :: ['sunitinib']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'low cancer', 'localised tumours', 'tumours']

entities_list: @entity1600 :: ('MESH:D014388', 'Disease') :: ['lymph node disease']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['lower back pain']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['aggressive subtype of renal cell carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['lymphovascular invasion']

entities_list: @entity9528 :: ('MESH:D005878', 'Disease') :: ['Constitutional syndrome']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal parenchymal tumour', 'carcinomas of the kidney', 'carcinoma of the kidney']

answer: @entity703 :: (MESH:D007680,Disease) :: ['carcinoma of the kidney']


abstract: UNASSIGNED: @entity2489 ( @entity2489 ) is a common @entity580 among intensive care unit (ICU) @entity1 . @entity796 (PA) is the most common multidrug-resistant Gram-negative pathogen and @entity2489 caused by PA carries a high rate of morbidity and mortality. This study examined the molecular mechanism of PA @entity2489 -induced @entity651 . C57BL/6 @entity164 ( @entity164 ) @entity19 and @entity14032 knockout ( @entity14032 -/-) @entity19 received mechanical ventilation (MV) for 3 h at 2 days after receiving nasal instillation of PA. The @entity164 and @entity14032 -/- @entity19 also received MV after the induction of @entity651 by instillation of supernatants from PA-stimulated alveolar macrophages (AMs). AMs isolated from @entity164 , @entity28293  Mye ( @entity28293 was selectively deleted in macrophages), and @entity14032 -/- @entity19 were ex vivo stimulated with live PA and supernatants were collected for cytokine assay. Intranasal instillation of 106 PA enhanced MV-induced NF-kB DNA binding activity in the lungs and @entity3542 levels in BALF. MV after PA instillation significantly increased the expression of ICAM and VCAM in the lungs and @entity637 , @entity635 , and @entity777 levels in bronchoalveolar lavage fluid (BALF) of @entity164 @entity19 , but not in @entity14032 -/- @entity19 . MV after supernatant instillation induced more total protein concentration in BALF and neutrophil sequestration in the lungs in @entity164 @entity19 than @entity14032 -/- @entity19 and cytokine assay of supernatants indicated that @entity637 is a critical regulator of PA @entity2489 -induced @entity651 . Ex vivo PA stimulation induced @entity637 production by AMs from @entity164 as well as @entity14032 -/- @entity19 but not @entity28293  Mye @entity19 . In summary, PA colonization plays an important role in PA @entity2489 -induced @entity651 through the induction of @entity14032 -mediated @entity32 . These results suggest that the pathogenesis mechanism of PA @entity2489 involves production of @entity637 through activation of IKK/NF-kB pathways in AMs and JNK signaling pathway in the lungs.

title: XXXX @entity2489 Induces @entity651 through @entity637 /c-Jun NH2-Terminal Kinase Pathways.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity796 :: ('287', 'Species') :: ['Pseudomonas aeruginosa']

entities_list: @entity3542 :: ('CHEBI:16301', 'Chemical') :: ['nitrite']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury']

entities_list: @entity2489 :: ('MESH:D053717', 'Disease') :: ['Ventilator-associated pneumonia', 'VAP']

entities_list: @entity580 :: ('MESH:D003428', 'Disease') :: ['nosocomial infection']

answer: @entity796 :: (287,Species) :: ['Pseudomonas aeruginosa']


abstract: We examined the effects of the @entity1289 ( @entity1289 ) inhibitors @entity3371 , enalaprilat, @entity9383 , and @entity21594 , and their active metabolites @entity23288 and trandolaprilat, on @entity2142 induced by @entity6579 ( @entity15002 ) in @entity1 erythrocytes. @entity15002 induced @entity2142 at the concentrations above the critical micelle concentration (4 microM). @entity1169 , used as a reference drug, attenuated the 50% @entity2142 induced by 6 microM @entity15002 at concentrations ranging from 100 nM to 100 microM. Similarly, @entity23288 (10 microM) and trandolaprilat (10, 100 microM) significantly attenuated the @entity15002 -induced @entity2142 , but other @entity1289 inhibitors did not. Since @entity1169 possesses a membrane stabilizing action correlated with high lipophilicity, it appears that the high lipophilicity of @entity23288 or trandolaprilat is responsible for the protection from the damage induced by @entity15002 . However, @entity9383 and @entity21594 were not effective, although both drugs have higher lipophilicity than @entity23288 and trandolaprilat. Hence, it is suggested that the high lipophilicity alone may not contribute to the protective effects of @entity1289 inhibitors against @entity15002 -induced @entity2142 . None of @entity1289 inhibitors attenuated the @entity2142 (60 mM @entity1219 ), although @entity1169 did. Furthermore, neither @entity1169 (100 microM) nor @entity23288 (50 microM) and trandolaprilat (50 microM) affected @entity15002 micelle formation, suggesting that these drugs do not directly bind to @entity15002 . We therefore believe that the protective effects of @entity23288 and trandolaprilat on the @entity15002 -induced @entity2142 may be related physicochemically to their highly lipophilic and @entity1289 inhibitory structures, which probably maintain erythrocyte membrane integrity by a mechanism other than @entity1289 inhibition, prevention of @entity15002 micelle formation or protection against osmotic imbalance.

title: Protective effects of @entity23288 and trandolaprilat, active metabolites of @entity9383 and @entity21594 , on @entity2142 induced by @entity6579 in XXXX erythrocytes.

entities_list: @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol', 'Propranolol']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme', 'ACE']

entities_list: @entity6579 :: ('MESH:D008244', 'Chemical') :: ['lysophosphatidylcholine']

entities_list: @entity9383 :: ('MESH:C041125', 'Chemical') :: ['quinapril']

entities_list: @entity3371 :: ('CHEBI:3380', 'Chemical') :: ['captopril']

entities_list: @entity23288 :: ('MESH:C054501', 'Chemical') :: ['quinaprilat']

entities_list: @entity2142 :: ('MESH:D006461', 'Disease') :: ['hemolysis', 'hypotonic hemolysis']

entities_list: @entity21594 :: ('MESH:C052035', 'Chemical') :: ['trandolapril']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: Robot-assisted gait training (RAGT) is effective for improving dynamic balance and aerobic capacity, but previous RAGT method does not set suitable training intensity. Recently, high-intensity treadmill gait training at 70% of heart rate reserve (HRR) was used for improving aerobic capacity and dynamic balance. PURPOSE: This study was designed to compare the effectiveness between objective and subjective methods of high-intensity RAGT for improving dynamic balance and aerobic capacity in @entity64 . METHODS: Subjects were randomly allocated into experimental (n  =  17) and control (n  =  17) groups. The experimental group underwent high-intensity RAGT at 70% of HRR, whereas the control group underwent high-intensity RAGT at an RPE of 15. Both groups received their assigned training for 30  min per session, 3  days per week for 6  weeks. All subjects also received an additional 30  min of conventional physical therapy. Before and after each of the 18 sessions, the dynamic balance and aerobic capacity of all subjects were evaluated by a blinded examiner. RESULTS: After training, @entity2653 ( @entity2653 ) and Timed Up and Go Test scores, VO2max, and VO2max/kg were significantly increased in both groups (p  <  0.05). These variables in experimental group were significantly greater than control group. However, the @entity2653 score was not significantly different between both groups. All subjects completed high-intensity RAGT. No adverse effect of training was observed in both groups. CONCLUSION: High-intensity RAGT at 70% of HRR significantly improved dynamic balance and aerobic capacity more than RAGT at RPE of 15. These results suggest that high-intensity RAGT at 70% of HRR is safe and effective for improving dynamic balance and aerobic capacity in @entity64 .

title: Comparison of the effects on dynamic balance and aerobic capacity between objective and subjective methods of high-intensity robot-assisted gait training in XXXX patients: a randomized controlled trial.

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['chronic stroke']

entities_list: @entity2653 :: ('MESH:C538175', 'Disease') :: ['Berg Balance Scale', 'BBS']

answer: @entity64 :: (MESH:D020521,Disease) :: ['chronic stroke']


abstract: BACKGROUND: Almost half of the @entity1 with @entity483 experience @entity32 of the eyelids, the conjunctiva and the @entity267 . @entity32 is a possible cause for the development of @entity5 , especially if associated with some kind of immunological defect as in @entity1097 @entity1 . So far, a correlation between @entity5902 and @entity5 has not yet been reported. Here, we present 7 @entity1097 @entity1 with @entity189 or @entity189 in situ detected between February 2000 and August 2001. @entity1 : All 7 @entity1 had a long history of @entity483 and @entity32 of the conjunctiva and @entity267 . In all @entity1 smears were examined by cytology and DNA cytometry. Furthermore, in 6 of the 7 @entity1 a histopathological examination of conjunctival biopsies was performed. RESULTS: In 4 of the 7 @entity1 invasive @entity189 and in 2 @entity189 in situ were detected. Cytology and cytometry revealed @entity189 or @entity189 in situ in the remaining @entity1 . Histopathological examination could not be performed since the @entity1 refused to have a conjunctival biopsy. CONCLUSIONS: These results suggest that @entity9849 might be a risk factor for the development of @entity189 .

title: [ XXXX : probably a risk factor for the development of @entity189 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity483 :: ('MESH:D003876', 'Disease') :: ['atopic dermatitis']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['chronic inflammation', 'chronic of inflammation', 'Chronic inflammation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['conjunctival malignancies', 'malignancies']

entities_list: @entity9849 :: ('MESH:D007637', 'Disease') :: ['atopic keratoconjunctivitis']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['conjunctival carcinoma', 'carcinoma']

entities_list: @entity5902 :: ('MESH:D003233', 'Disease') :: ['atopic conjunctivitis']

answer: @entity9849 :: (MESH:D007637,Disease) :: ['Atopic keratoconjunctivitis']